Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease

Purpose: The aim of the study was to evaluate the activity o vinorelbine (VNLB) in a population of ad-vanced ovarian cancer patients, with particular attention to defining its role in platinum-resistant disease. Patients and Methods: Thirty-three patients were re-cruited and treated with VNLB 25 mg/m 2 intravenously (IV) weekly. The median age was 53 years, performance status 0 to 2, and number of previous chemotherapy reg-imens two (range, one to five). Twenty-four patients were platinum-resistant; the remaining nine either were plati-num-sensitive (four cases) or had undetermined sensitiv-ity (five cases). Results: The mean delivered dose-intensity of VNLB was 67 % of the planned level, because 60 % of the cycles were delayed due to neutropenia or anemia. Four partia